investors     Since ACT initiated operations in October 2007, ACT has successfully raised over $8 million from private investors in Kentucky alone, and is on schedule to reach its goal of raising a total of $10 million by the end of 2009. ACT intends to efficiently deploy these funds to advance one or more compounds from its product pipeline up to or through Phase 1 human clinical trials and then explore strategic partnering options with leading pharmaceutical and biotechnology companies.